EMA Aims to Develop Guideline for mRNA Vaccines
EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically.
The European Medicines Agency (EMA) has created a concept paper that addresses the need to establish a guideline on the quality aspects of messenger RNA (mRNA) vaccines, emphasizing the number of clinical trial applications and marketing authorization applications for mRNA-containing products significantly increasing over the past few years and still growing.
Further, EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically. New technology for these types of vaccines is not fully accounted for in the existing guidance, which is why a newer guidance is necessary for EMA to highlight specific aspects regarding the manufacturing process, characterization, specifications, and analytical control for mRNA vaccines for the prevention of infectious disease.
According to the company press release, the scope of the guideline will be limited to mRNA vaccines against infectious diseases. Further, mRNA-based therapeutics will be out of scope of the document, and it is not intended to address specific requirements for mRNA vaccines to be used in clinical trials.
Source: EMA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
